Premium
Identification of sphingolipids as novel noninvasive biomarkers of liver damage caused by chronic hepatitis B
Author(s) -
Qu Feng,
Zheng SuJun,
Liu Shuang,
Jin Ying,
Zhang JinLan,
Duan ZhongPing
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.815.1
Subject(s) - sphingolipid , cirrhosis , receiver operating characteristic , chronic hepatitis , medicine , area under the curve , gastroenterology , biology , pathology , immunology , biochemistry , virus
Sphingolipids are key components in the viral life cycle that affects host‐pathogen interactions. In this study, a total of 98 subjects were classified as either healthy control (n=28), chronic hepatitis B (n=23), cirrhosis (n=21), or acute‐on‐chronic liver failure patients (n=26), according to the clinical tests. The serum levels of 43 sphingolipids were detected by high performance liquid chromatography tandem mass spectrometry. Biometrical methods were used to identify and evaluate the potential biomarkers. Sphingolipid patterns differed substantially between the four stages. Sixteen sphingolipids were identified as potential biomarkers. Receiver operating characteristic analysis demonstrated that 15 of them showed significant diagnostic performance (area under the curve (AUC) >; 0.7), especially in distinguishing cirrhosis from chronic hepatitis B (AUC >; 0.9). A marked improvement of diagnostic performance was achieved by combining biomarkers using logistic regression. Significant correlations between sphingolipids, measures of liver damage (MELD and Child‐Pugh scores) and HBV DNA levels were also obtained. Our study revealed that HBV alters sphingolipid metabolism, and sphingolipids hold promise as novel noninvasive biomarkers of HBV caused liver damage. Ministry of Science and Technology of China (2012ZX09301002–006)